Granahan Investment Management’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Granahan Investment Management’s Portfolio VYNT Stock Details VYNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,819	Closed	-$66K	–	206
2018 Q4	$66K	Sell	1,819 -36	-2%	-$3.04K	﹤0.01%	193
2018 Q3	$289K	Buy	1,855 +12	+0.7%	+$1.78K	0.02%	193
2018 Q2	$246K	Buy	1,843 +273	+17%	+$41.3K	0.01%	199
2018 Q1	$389K	Sell	1,570 -126	-7%	-$35.5K	0.03%	190
2017 Q4	$471K	Buy	1,696 +113	+7%	+$43.1K	0.04%	187
2017 Q3	$641K	Buy	1,583 +329	+26%	+$172K	0.05%	164
2017 Q2	$743K	Buy	+1,254	New	+$733K	0.07%	161

Other funds holding VYNT

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Fairbanks Capital Management Rancho Santa Fe, California $169M AUM 12.21% 1-Year Est. Return

Diker Management New York $112M AUM 59.78% 1-Year Est. Return

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Granahan Investment Management's VYNT Position: Q1 2019 in Review

Granahan Investment Management sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2019, closing a stake of 1,819 shares — an estimated $66K sold.

Granahan Investment Management first reported a position in VYNT in Q2 2017 and held it in 7 quarters. The position peaked at $743K in Q2 2017. 24 funds tracked by Wall St. Rank hold VYNT as of Q1 2019.

Granahan Investment Management reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Granahan Investment Management sold 1,819 Vyant Bio, Inc. Common Stock shares in Q1 2019, an estimated $66K.
Granahan Investment Management first reported a position in Vyant Bio, Inc. Common Stock in Q2 2017 and held it in 7 quarters.
Granahan Investment Management's Vyant Bio, Inc. Common Stock position peaked at $743K in Q2 2017.
24 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2019.

Based on Granahan Investment Management's 13F filing for Q1 2019, filed 14 May 2019.